CRIS Current Research Information System

TESTONI, NICOLETTA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.533
EU - Europa 6.916
AS - Asia 3.131
AF - Africa 509
SA - Sud America 20
OC - Oceania 9
Continente sconosciuto - Info sul continente non disponibili 8
Totale 19.126
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.499
GB - Regno Unito 2.148
VN - Vietnam 1.477
SE - Svezia 1.345
CN - Cina 999
IT - Italia 875
DE - Germania 845
IN - India 373
IE - Irlanda 300
FR - Francia 278
UA - Ucraina 242
RU - Federazione Russa 226
TG - Togo 179
ZA - Sudafrica 157
EE - Estonia 151
CH - Svizzera 122
BG - Bulgaria 99
JO - Giordania 92
CI - Costa d'Avorio 84
FI - Finlandia 80
GR - Grecia 77
NG - Nigeria 65
BE - Belgio 56
IR - Iran 40
CA - Canada 33
TR - Turchia 25
SG - Singapore 24
SC - Seychelles 23
JP - Giappone 16
KR - Corea 13
LB - Libano 13
NL - Olanda 13
PH - Filippine 12
BR - Brasile 11
RO - Romania 11
HK - Hong Kong 10
UZ - Uzbekistan 10
AT - Austria 9
CZ - Repubblica Ceca 8
AU - Australia 7
ES - Italia 6
EU - Europa 6
MY - Malesia 6
CL - Cile 5
ID - Indonesia 5
SA - Arabia Saudita 5
HR - Croazia 4
PL - Polonia 4
MK - Macedonia 3
PT - Portogallo 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BA - Bosnia-Erzegovina 2
IL - Israele 2
KZ - Kazakistan 2
LU - Lussemburgo 2
NO - Norvegia 2
NZ - Nuova Zelanda 2
PE - Perù 2
RS - Serbia 2
TW - Taiwan 2
AL - Albania 1
AM - Armenia 1
BD - Bangladesh 1
BO - Bolivia 1
EC - Ecuador 1
EG - Egitto 1
HU - Ungheria 1
IQ - Iraq 1
KW - Kuwait 1
LK - Sri Lanka 1
MX - Messico 1
SM - San Marino 1
Totale 19.126
Salva come PNG Salva come JPEG
Città #
Southend 1.999
Chandler 1.091
Fairfield 1.066
Dong Ket 1.000
Ashburn 664
Woodbridge 538
Houston 527
Wilmington 512
Ann Arbor 494
Seattle 481
Princeton 377
Cambridge 373
Dublin 300
Beijing 207
Lomé 179
Westminster 178
Nanjing 164
Padova 162
Bologna 153
New York 121
Jacksonville 114
Berlin 113
Bern 104
Sofia 95
Turin 93
Amman 92
Medford 87
Abidjan 84
Jinan 81
Bremen 76
Saint Petersburg 76
Shenyang 76
Hebei 74
Helsinki 65
Abeokuta 63
Boardman 62
Brussels 55
Falls Church 55
Nanchang 55
San Diego 55
Florence 51
Changsha 47
Redwood City 41
Redmond 39
Jiaxing 38
Milan 38
Tianjin 35
Norwalk 29
Hangzhou 26
Mülheim 26
Zhengzhou 24
Mountain View 23
Paris 23
Taizhou 23
Mahé 22
Des Moines 20
Haikou 20
Dearborn 19
Guangzhou 18
Washington 18
Istanbul 17
Zanjan 17
Ningbo 16
Andover 15
Athens 15
Busseto 15
Lappeenranta 15
Taiyuan 15
Frankfurt am Main 14
Leawood 14
Los Angeles 14
Bühl 13
Monmouth Junction 12
Olalla 12
Toronto 12
North York 11
Fabriano 10
Grafing 10
Singapore 10
Tokyo 10
Verona 10
Frankfurt Am Main 9
Phoenix 9
Augusta 8
Castelfranco Emilia 8
Davao City 8
Fuzhou 8
Kiev 8
Pune 8
Faenza 7
Henderson 7
Kunming 7
Ardabil 6
Bo 6
Chengdu 6
Groningen 6
Hong Kong 6
Kilburn 6
Kuban 6
Lanzhou 6
Totale 13.153
Salva come PNG Salva come JPEG
Nome #
Aneuploid acute myeloid leukemia exhibits a signature of genomic alterations in the cell cycle and protein degradation machinery 268
A Specific Pattern of Somatic Mutations Associates with Poor Prognosis Aneuploid Acute Myeloid Leukemia: Results from the European NGS-PTL Consortium 228
Adult "Triple Negative" ACUTE Lymphoblastic Leukemia Genome Wide Characterization 219
B-cell acute lymphoblastic leukemia as evolution of a 8p11 myeloproliferative syndrome with t(8;22)(p11;q11) and BCR-FGFR1 fusion gene. 212
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia 210
Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients. 210
Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience 206
A NEW SUBSET OF ADULT B CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENT WITH PREDNISONE-INDUCED MONOCYTIC DIFFERENTIATION? 203
Aggressive Aneuploid Acute Myeloid Leukemia Is Dependent on Alterations of P53, Gain of APC and PLK1 and Loss of RAD50 203
Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis 192
Alterations in phosphatidylinositol 3-phosphate (PI3P) pathway and cAMP pathway confirm poor prognosis and reduced overall survival (OS) in a series of 209 acute myeloid leukemia patients 184
Chromothripsis in acute myeloid leukemia: Biological features and impact on survival 180
Alterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML) 177
The alteration in key regulator genes of autophagy is mainstream mechanism of therapy resistance and impact prognosis of acute myelogenous leukemia (AML): results from diagnosis genomic analysis on 148 consecutive patients treated with intensive chemotherapy and long-term survival follow-up 173
A novel t(2;10)(q31;p12) balanced translocation in acute myeloid leukemia 167
Chromothripsis in Acute Myeloid Leukemia Is Strongly Associated with Poor Prognosis and TP53 Alterations 167
BCR-ABL1-associated reduction of beta catenin antagonist Chibby1 in chronic myeloid leukemia. 166
Alterations of BRCA1 and PALB2 Define a Novel Class of Complex-Karyotype AML with a Very Bad Prognosis 163
Molecular response to imatinib in late chronic-phase chronic myeloid leukemia 162
Positron emission tomography with computed tomography-based diagnosis of massive extramedullary progression in a patient with high-risk multiple myeloma. 161
Chromosome abnormalities additional to the Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: pathogenetic and prognostic implications. 160
Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia 159
A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: retrospective analysis of 530 patients. 158
Novel and rare fusion transcripts involving transcription factors and tumor suppressor genes in acute myeloid leukemia 154
Identification of a novel t(1;9)(q11;q34) in acute myelocytic leukemia 148
CLINICAL OUTCOMES PREDICTION FOR NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH THALIDOMIDE-DEXAMETHASONE AND AUTOLOGOUS STEM CELL TRANSPLANTATION BY 8-GENE SIGNATURE OF CD138+ PLASMA CELLS 148
A cell cycle-related genomic and transcriptomic signature distinguish aneuploid and euploid acute myeloid leukemia 147
Efficacy and clinical outcome of Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL) patients treated with second generation tyrosine kinase inhibitors (TKIs): The Bologna experience 146
Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment. 145
Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: Molecular cytogenetic characterization and influence on TKIs therapy 145
ACTIVATION-INDUCED CYTIDINE DEAMINASE IS ABERRANTLY OVEREXPRESSED IN BCRABL1 POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA CELLS AND PROMOTES DNA-SINGLE STRAND BREAKS 144
Acute promyelocytic leukemia with amplification of PML-RARalpha rearrangement:clinical implications 144
Evaluation of bone disease in multiple myeloma patients carrying the t(4;14) chromosomal translocation. 133
Epigenetically induced ectopic expression of uncx impairs the proliferation and differentiation of myeloid cells 133
Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response, a study of the GIMEMA CML WP. 133
Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib. 130
Influence of additional cytogenetic abnormalities on the response and survival in late chronic phase chronic myeloid leukemia patients treated with imatinib: long-term results. 130
Philadelphia positive (Ph+) acute lymphoblastic leukemia (ALL) patient with breast infiltration 129
Complex chromosomal rearrangements leading to MECOM overexpression are recurrent in myeloid malignancies with various 3q abnormalities 129
MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemia 129
Association of 3q21q26 syndrome with different RPN1/EVI1 fusion transcripts 126
Cytoplasmic mutated nucleophosmin (NPM1) in blast crisis of chronic myeloid leukaemia. 125
Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response 123
Distinct pattern of alterations in tp53 mutated and wild type acute myeloid leukemia (AML) patients 122
4q12 translocations with GSX2 expression identify a CD7+ acute myeloid leukaemia subset 121
CLINICAL OUTCOME OF T-ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOMA (T-ALL/TLBL): THE BOLOGNA EXPERIENCE 121
Opposite activation of the Hedgehog pathway in CD138+ plasma cells and CD138-CD19+ B cells identifies two subgroups of patients with multiple myeloma and different prognosis 121
Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia 121
Copy number variants signature in two patients with relapsed acute promyelocytic leukemia 119
Correlation between eight-gene expression profiling and response to therapy of newly diagnosed multiple myeloma patients treated with thalidomide–dexamethasone incorporated into double autologous transplantation 118
NPM1 mutations are more stable than FLT3 mutations during the course of disease in patients with acute myeloid leukemia. 117
Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. 116
Deficient necroptosis pathway as a negative prognostic factor in acute myeloid leukemia. 116
Efficacy and Feasibility of Nelarabine Savage Therapy In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) Strongly Indicates the Introduction of a Nelarabine-Based First Line Regimen 116
Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis. 116
Prognostic impact of serial measurements of serum-free light chain assay throughout the course of newly diagnosed multiple myeloma treated with bortezomib-based regimens 115
Efficacy and Feasibility of Nelarabine Savage Therapy In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) Strongly Indicates the Introduction of a Nelarabine-Based First Line Regimen 115
Case-control study of multidrug resistance phenotype and response to induction treatment including or not fludarabine in newly diagnosed acute myeloid leukaemia patients. 115
Fludarabine, Cytarabine, Idarubicin and Etoposide (FLAIE) schedule is safe and active for young patients with newly diagnosed acute myeloid leukemia (AML): Results of a multicentric phase III Italian study 115
Mesenchymal stromal cells from myelodysplastic and acute myeloid leukemia patients display in vitro reduced proliferative potential and similar capacity to support leukemia cell survival 115
Molecular and chromosomal alterations: new therapies for relapsed acute myeloid leukemia. 114
CLINICAL OUTCOME OF T- ACUTE LYMPHOBLASTIC LEUKEMIA/ LYMPHOMA (T-ALL/T-LBL): THE BOLOGNA EXPERIENCE 114
Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study 114
Very Poor Outcome and Chemoresistance of Acute Myeloid Leukemia Patients with TP53 Mutations: Correlation with Complex Karyotype and Clinical Outcome 113
Impact on survival of catastrophic karyotype events in 101 consecutive acute myeloid leukemia (AML) patients: High risk karyotype and chromothripsis 112
Presence or the Emergence of a F317L BCR-ABL Mutation May Be Associated With Resistance to Dasatinib in Philadelphia Chromosome Positive Leukemia 112
Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party. 112
Gemtuzumab-Ozogamicin Containing Regimens As Induction Therapy Give the Highest Complete Remission Rate and the Longest Overall Survival Compared with Other Induction Regimens in Patients with Newly Diagnosed Acute Myeloid Leukemia 111
Poor outcome with front-line autologous transplantation in t(4;14) multiple myeloma: low complete remission rate and short duration of remission. 109
Pediatric-Like Intensified Therapy In Adult Acute Lymphoblastic Leukemia: A Single Centre Experience 109
AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features. 109
Two or More Chemotherapy Consolidation Courses, Followed By Autologous Bone Marrow Transplantation, and MRD Negativity, Give Long Term Overall Survival in Acute Myeloid Leukemia Patients 109
SIRPB1 Is a Strong Predictor Biomarker of Response to 5-Azacitidine Therapy in MDS and AML Patients 108
Molecular and cytogenetic characterization of a new case of t(5;17)(q35;q21) variant acute promyelocytic leukemia 107
Complex karyotype, older age, and reduced first-line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with long-term follow-up 106
Interleukin-12 production by leukemia-derived dendritic cells counteracts the inhibitory effect of leukemic microenvironment on T cells. 105
Revealing very small FLT3 ITD mutated clones by ultra-deep sequencing analysis has important clinical implications in AML patients 105
null 104
Dissecting the Molecular Mechanisms of Aneuploidy in Acute Myeloid Leukemia By Next Generation Sequencing 104
The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase. 103
Microarray analysis to identifiy novel copy number alterations in acute myeloid leukemia 103
Loss of PALB2 predicts poor prognosis in acute myeloid leukemia and suggests novel therapeutic strategies targeting the DNA repair pathway 103
null 102
Efficacy of Azacitidine in the treatment of adult patients aged 65 years or older with AML 102
Efficacy and clinical outcome of Philadelphia positive Acute Lymphoblastic Leukemia patients treated with second generation tyrosine kinase inhibitors (TKIS): the Bologna experience 101
Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia. 101
EFFICACY, FEASIBILITY AND SAFETY OF NELARABINE SAVAGE THERAPY IN ADULT RELAPSED OR REFRACTORY T CELL ACUTE LYMPHOBLASTIC LEUKEMIA (T-ALL) OR LYMPHOBLASTIC LYMPHOMA (T-LBL): THE BOLOGNA EXPERIENCE 100
Long-term follow-up of 386 consecutive patients with essential thrombocythemia: safety of cytoreductive therapy. 100
Low-level Bcr-Abl mutations are very rare in chronic myeloid leukemia patients who are in major molecular response on first-line nilotinib 100
A New Entity of Acute Myeloid Leukemia Driven By Epigenetic and Somatic Dis-Regulation of Uncx, a Novel Homeobox Transcription Factor Gene 100
Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma 99
Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML. 98
Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. 98
MHC-I Antigen Presentation Role in Immune Escape of Acute Myeloid Leukemia with High Burden of Genomic Aberration 98
Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of patients with high risk, Philadelphia-positive, chronic myeloid leukaemia: a European LeukemiaNet study 98
Separase overexpression defines a new subset of acute myeloma leukemia patients characterized by high CD34 and MYC levels 98
Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatment 98
null 98
Emergence of clonal chromosomal abnormalities in Philadelphia negative hematopoiesis in chronic myeloid leukemia patients treated with nilotinib after failure of imatinib therapy 97
Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells 97
Totale 13.239
Salva come PNG Salva come JPEG
Categoria #
all - tutte 44.494
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 44.494
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019341 0 0 0 0 0 0 0 0 0 0 90 251
2019/20204.849 694 155 26 332 501 470 577 569 650 355 229 291
2020/20213.296 475 209 91 69 48 132 56 196 268 115 206 1.431
2021/20224.045 530 94 230 402 366 234 69 264 173 325 687 671
2022/20234.453 493 718 236 583 310 377 130 229 697 109 374 197
2023/20241.182 65 168 75 143 87 309 68 98 33 74 62 0
Totale 19.656